Where Does Rani Therapeutics (NASDAQ:RANI) Stand After Its Third-Quarter Update?

Sonal Goyal

10 November 2026 06:56 PM AEDT

Where Does Rani Therapeutics (NASDAQ:RANI) Stand After Its Third-Quarter Update?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Contract Revenue was $1.7 million for the quarter ended September 30, 2026.
Cash, cash equivalents and marketable securities totaled $45.3 million at September 30, 2026.
The company reported acceptance into the FDA's Emerging Technology Program.
The contract revenue increase was attributed to a collaboration and license agreement with Chugai.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported third-quarter 2026 contract revenue of $1.7 million, compared with no contract revenue in the same period of 2025. The Fremont, California-based clinical-stage biotherapeutics company focuses on oral delivery of Biologics through its RaniPill platform. Cash, cash equivalents and marketable securities totaled $45.3 million at September 30, 2026.

Contract Revenue

Contract revenue for the three months ended September 30, 2026, was $1.7 million, compared with no contract revenue for the same period of 2025. The increase was primarily attributable to a collaboration and license agreement with Chugai, according to the company's report of its results.

Contract revenue is recognized under the terms of collaboration agreements, which set out payments for licenses, development services and other milestones.

Regulatory and Platform Update

The chief executive described the third quarter as one of continued progress for the RaniPill platform.

The company's update covers the status of its RaniPill platform, which is designed to deliver biologic drugs orally. Oral delivery of biologics is a development area that has been pursued across the pharmaceutical industry.

Cash Position

Cash, cash equivalents and marketable securities totaled $45.3 million as of September 30, 2026. The company said that balance supports operations for a period that it described in its report. The company's cash balance and its planned expenses are set out in its financial statements.

Clinical-stage companies report net losses while their development programs are underway, and their cash balances are used to fund research, Clinical Trials and administrative costs.

Final Word

Rani Therapeutics reported third-quarter 2026 contract revenue of $1.7 million, cash, cash equivalents and marketable securities of $45.3 million as of September 30, 2026, and acceptance into the FDA Emerging Technology Program for its RaniPill platform.

FAQs

Q: What was Rani Therapeutics' contract revenue in the third quarter?

A: Contract revenue was $1.7 million for the quarter ended September 30, 2026.

Q: How much cash did the company report?

A: Cash, cash equivalents and marketable securities totaled $45.3 million at September 30, 2026.

Q: What did the FDA accept?

A: The company reported acceptance into the FDA's Emerging Technology Program.

Q: What platform does the company develop?

A: Rani Therapeutics develops the RaniPill platform for oral delivery of biologics.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.